Kangdesai Medical Technology

China
Chengdu, Sichuan, China

Company profile

Kangdesai Medical Technology company profile

Kandesai is a personalized tumor immunotherapy developer, focusing on the development of immunotherapy platforms based on tumor neoantigens. It has independently developed 3 tumor drug pipelines based on neoantigens and innovative pipelines for liver cirrhosis with independent intellectual property rights. Help patients suppress tumor recurrence and metastasis.

Business identity

Contact email
[email protected]
Phone number
+86 028-69261055
Operating status
Active
Company type
For Profit
Employee range
51-100 employees
Founded
2016-11-07

Headquarters

Country code
CN
Continent
Asia

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
2
Total equity funding
$7.8M
Last funding
Series A / 2025-09-22
Last equity funding
Series A
Investors
7
Lead investors
2
Founders
1

Founders and investors

Founders

Ping Ding

Lead investors

Dongna FundKorea Investment Partners

Investors

Aier Eye Hospital GroupBeijing Enterprises Medical and Health Industry GroupChongqing Lummy PharmaceuticalKorea Investment PartnersShenzhen Baichuan Yingzhi Investment Development